Skip to main content
. 2015 Jan 8;26(1):54–61. doi: 10.3802/jgo.2015.26.1.54

Fig. 1.

Fig. 1

Disease-free (A) and overall survival (B) in 54 patients with primary advanced or recurrent ovarian cancer treated with cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel.